Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.
Study of plasma-derived miRNAs mimic differences in Huntington's disease brain.
复制标题
DOI：
10.1002/mds.26457
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Latourelle JC
中科院分区：
文献类型：
--
作者：
Hoss AG;Lagomarsino VN;Frank S;Hadzi TC;Myers RH;Latourelle JC
亨廷顿病（HD）进展的生物标志物可以加速治疗发展并改善患者护理。与HD临床特征相关的脑微小核糖核酸（miRNA）可能是血液中一种潜在的HD生物标志物。
检测血浆中的候选miRNA，以确定在HD大脑中观察到的变化是否能在外周样本中检测到。
使用逆转录定量聚合酶链反应（RT - qPCR）对26例显性HD患者、4例无症状HD基因携带者和8例对照者的血浆中的4种miRNA进行定量。采用线性回归评估对照组、无症状基因携带者和显性患者之间的miRNA水平。
miR - 10b - 5p（p = 0.0068）和miR - 486 - 5p（p = 0.044）在HD血浆中升高。与HD患者相比，无症状基因携带者中miR - 10b - 5p降低（p = 0.049），但无症状基因携带者和对照组之间未观察到差异（p = 0.24）。
这些发现表明，在HD大脑中观察到的miRNA变化可能在血浆中可检测到，并具有潜在的临床应用价值。
Biomarkers for Huntington’s disease (HD) progression could accelerate therapeutic developments and improve patient care. Brain microRNAs (miRNA) relating to clinical features of HD may represent a potential HD biomarker in blood. Examine candidate miRNAs in plasma to determine if changes observed in HD brains are detectable in peripheral samples. Four miRNA from 26 manifest HD, 4 asymptomatic HD gene carriers and 8 controls were quantified in plasma using RT-qPCR. Linear regression was used to assess miRNA levels across control, asymptomatic gene carriers and manifest patients. miR-10b-5p (p= 0.0068) and miR-486-5p (p= 0.044) were elevated in HD plasma. miR-10b-5p was decreased in asymptomatic gene carriers as compared to HD patients (p= 0.049), but no difference between asymptomatic gene carriers and controls was observed (p= 0.24). These findings suggest miRNA changes observed in HD brain may be detectable in plasma and have potential clinical utility.